Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin ...

The COMP005 study (NCT05624268) evaluated a placebo against COMP360, a synthetic, proprietary formulation of psilocybin, for ...

A single dose of psilocybin coupled with “talk therapy” can significantly reduce depression in people with cancer for up to ...

A single 25 mg dose of psilocybin, paired with psychological support, brought lasting relief from depression and anxiety in ...

Understanding early autism evaluations and why it matters whether a developmental pediatrician or a clinical psychologist ...

A first-of-its-kind clinical trial shows that ketamine treatment for severe, treatment-resistant depression is significantly ...

Depression subtype, age, and prior attempts shaped suicide risk and costs in older adults receiving psychiatric care.

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

Researchers from China Agricultural University discovered that a specific gut bacteria strain can tackle both depression and ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

About half of patients had sustained reduction in depression and anxiety up to two years after psilocybin and psychotherapy.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...